Anna Nergärdh1, Rolf Nordlander, Mats Frick. 1. Department of Cardiology, Karolinska Institute at Stockholm South Hospital, Stockholm, Sweden. anna.nergardh@sodersjukhuset.se
Abstract
BACKGROUND: A number of patients with persistent atrial fibrillation (AF) will not have sinus rhythm (SR) restored by direct current (DC) cardioversion. HYPOTHESIS: In patients with DC-refractory AF, oral pretreatment with sotalol increases the success rate at DC cardioversion. METHODS: Consecutive patients with persistent AF, refractory at a first DC cardioversion, were prospectively included. A comparative group of patients with AF not refractory at DC cardioversion was studied. Oral sotalol treatment was started after unsuccessful DC cardioversion and given at least 7 days before renewed cardioversion. Four weeks after cardioversion, an electrocardiogram was performed. RESULTS: In all, 53 patients were enrolled in the study. Forty-three (81%) in the sotalol group regained sinus rhythm (SR): 10 (19%) of these converted pharmacologically and 33 (62%) after a second DC cardioversion; SR was never restored in 10 patients (19%). After 4 weeks, SR was maintained in 29 patients (67%). The comparative group included 132 patients and differed significantly from the DC-refractory patients only with regard to weight. After 4 weeks, SR was maintained by 50 patients (37%) in this group. CONCLUSIONS: In patients with persistent AF refractory to DC cardioversion, oral pretreatment with sotalol results in a high rate of SR restoration, either pharmacologically or by DC cardioversion. Maintenance of SR at 4 weeks is of sufficient clinical relevance to consider this treatment option in patients with AF refractory to DC cardioversion.
BACKGROUND: A number of patients with persistent atrial fibrillation (AF) will not have sinus rhythm (SR) restored by direct current (DC) cardioversion. HYPOTHESIS: In patients with DC-refractory AF, oral pretreatment with sotalol increases the success rate at DC cardioversion. METHODS: Consecutive patients with persistent AF, refractory at a first DC cardioversion, were prospectively included. A comparative group of patients with AF not refractory at DC cardioversion was studied. Oral sotalol treatment was started after unsuccessful DC cardioversion and given at least 7 days before renewed cardioversion. Four weeks after cardioversion, an electrocardiogram was performed. RESULTS: In all, 53 patients were enrolled in the study. Forty-three (81%) in the sotalol group regained sinus rhythm (SR): 10 (19%) of these converted pharmacologically and 33 (62%) after a second DC cardioversion; SR was never restored in 10 patients (19%). After 4 weeks, SR was maintained in 29 patients (67%). The comparative group included 132 patients and differed significantly from the DC-refractory patients only with regard to weight. After 4 weeks, SR was maintained by 50 patients (37%) in this group. CONCLUSIONS: In patients with persistent AF refractory to DC cardioversion, oral pretreatment with sotalol results in a high rate of SR restoration, either pharmacologically or by DC cardioversion. Maintenance of SR at 4 weeks is of sufficient clinical relevance to consider this treatment option in patients with AF refractory to DC cardioversion.
Authors: H Li; A Natale; G Tomassoni; S Beheiry; P Cooper; F Leonelli; A Easley; W Barrington; J Windle Journal: Am J Cardiol Date: 1999-11-01 Impact factor: 2.778
Authors: W L Henry; J Morganroth; A S Pearlman; C E Clark; D R Redwood; S B Itscoitz; S E Epstein Journal: Circulation Date: 1976-02 Impact factor: 29.690
Authors: Richard L Page; Richard E Kerber; James K Russell; Tom Trouton; Johan Waktare; Donna Gallik; Jeff E Olgin; Philippe Ricard; Gavin W Dalzell; Ramakota Reddy; Ralph Lazzara; Kerry Lee; Mark Carlson; Blair Halperin; Gust H Bardy Journal: J Am Coll Cardiol Date: 2002-06-19 Impact factor: 24.094